

# Efficacy and safety of acupuncture therapy for psoriasis: an overview of systematic reviews

# Mingyi Jing<sup>1,2#</sup>, Lanhui Shi<sup>1#</sup>, Yuzhen Zhang<sup>1#</sup>, Mei Zhu<sup>1#</sup>, Fan Yuan<sup>2</sup>, Baohua Zhu<sup>1,2</sup>, Mingling Chen<sup>1,2</sup>, Xiaopei Ge<sup>1</sup>

<sup>1</sup>Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China; <sup>2</sup>School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China

*Contributions:* (I) Conception and design: M Jing, L Shi, X Ge; (II) Administrative support: Y Zhang, M Zhu, F Yuan; (III) Provision of study materials or patients: M Jing, M Chen, B Zhu; (IV) Collection and assembly of data: L Shi, Y Zhang, M Zhu; (V) Data analysis and interpretation: M Jing, X Ge; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

<sup>#</sup>These authors contributed equally to this work and are co-first authors.

Correspondence to: Xiaopei Ge. Hospital of Chengdu University of Traditional Chinese Medicine, No.39 Shi-er-qiao Road, Chengdu 610075, China. Email: Gdgexiaopei@126.com.

**Background:** Acupuncture therapy is a method of piercing needles into acupoints to treat diseases with/ without corresponding manipulations, which could serve as a useful supplementary therapy for psoriasis. The present study aimed to outline and sum up current evidence from systematic reviews (SRs)/meta-analyses (MAs) that investigate the clinical efficacy of acupuncture on psoriasis.

Methods: A comprehensive search involving eight electronic databases was conducted from the date of inception to July 2021, and grey literatures were manually searched. The research was selected according to prespecified inclusion criteria and relevant data were obtained. The methodological quality of the included SRs was scrutinized using the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2) tool. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was used to appraise the reporting quality of the included SRs. Risk of Bias in Systematic Reviews (ROBIS) was selected for the evaluation of bias risk of the included SRs. Grading of Recommendations Assessment, Development, and Evaluation (GRADE) was applied to determine the quality of evidence from primary outcome measures. Results: After screening, seven SRs/MAs met the inclusion criteria, including two English and five Chinese articles. All of the SRs were published between 2015 and 2020. Based on AMSTAR-2, the quality of all SRs was rated as dangerously low. Using the PRISMA-A checklist, major reporting flaws were observed in the financial statements, protocols, and registrations of the included literature. According to the ROBIS tool, two SRs/MAs were classed as low bias risk. Using the GRADE tool, this review contained 27 outcomes, with only one being classified as high-quality evidence, seven moderate-quality evidences, and 19 as low-quality evidence. The present research results advocated acupuncture therapy as a supplementary treatment for psoriasis patients; however, the evidence should still be treated with caution due to certain limitations.

**Conclusions:** Our overview suggests that acupuncture could be used as a complementary therapy to produce effective clinical result for psoriasis. Nonetheless, considering the poor quality of SRs/Mas that advocate these findings, studies with more rigorous design, larger populations samples and of higher quality are called for to provide stronger evidence for definitive conclusions.

Keywords: Acupuncture; psoriasis; overview; systematic reviews (SRs); therapy

Submitted Aug 13, 2021. Accepted for publication Oct 09, 2021. doi: 10.21037/apm-21-2523 View this article at: https://dx.doi.org/10.21037/apm-21-2523

#### Introduction

Psoriasis is a chronic inflammatory skin disease mediated by the immune system, and its clinical hallmarks are welldefined, erythematous plaques covered by silvery-white scales, typically appearing symmetrically on the elbows, knees, trunk, and scalp with or without pruritus (1,2). Globally, the prevalence of psoriasis is approximately 2%, however this varies from region to region (3,4). Its prevalence is lower in Asian and some African populations, but is as high as 11% in Caucasian and Scandinavian populations (4-7). The factors influencing the progression of psoriasis include intrinsic (such as obesity, diabetes mellitus, dyslipidemia, hypertension, and mental stress) and extrinsic risk factors (such as air pollutants, UV exposure, mechanical stress, drugs, vaccination, infection, and individual lifestyle) (8). Psoriasis has a long course of disease with a high relapse rate, leading to a major decline in quality of life (QoL). The goal of treatment is to reduce disease severity and improve the QOL of patients (9).

The specific treatment approach for psoriasis is dependent on disease severity, comorbidities, and access to health care. Patients with psoriasis are often classified into mild or moderate to severe based on the extent of clinical manifestation, the percentage of total body surface affected, and the impact on QOL (10). Topical therapy is the standard of care for treating mild to moderate disease. Mild psoriasis can be treated topically with corticosteroids (11). Vitamin D analogues are the first choice for the treatment of plaque psoriasis and moderate to severe scalp psoriasis (12). Evidence has shown that calcipotriol combined with betamethasone propionate is more effective than either monotherapy alone in the treatment of psoriasis (13). Systemic treatment, such as phototherapy, methotrexate, cyclosporine, and acitretin, is usually preferred for moderate to severe psoriasis when topical agents do not take effect; and methotrexate can be also used for psoriatic arthritis (12,14,15). If traditional treatment is ineffective, biological agents are an effective treatment (16). However, most of these treatments have significant side effects (17,18) and high financial costs that limit their long-term use. Therefore, some clinicians and researchers have been looking for better treatments. Acupuncture therapy is considered as a characteristic traditional Chinese medicine therapy, which has been widely adopted in treating psoriasis in recent years. In particular, fire acupuncture has significant therapeutic effect on psoriasis with less side effects and low recurrence rate.

In short, acupuncture therapy has good clinical efficacy and low incidence of adverse reactions, and it is an ideal method for the treatment of psoriasis. The innovation of this paper is to reorganize the latest literatures and include the relevant literatures of fire acupuncture in the treatment of psoriasis for the first time, so as to make a comprehensive and systematic evaluation of acupuncture therapy for psoriasis, and evaluate the effectiveness and safety of acupuncture therapy for psoriasis.

Psoriasis is a common disease in dermatology with unknown etiology. Until now, there are no specific drugs and methods for psoriasis. Acupuncture can effectively reduce thickness, scales of the lesions and skin itching with fewer side effects, and its importance is being recognized increasingly. In recent years, a growing number of experts have realized the advantages of acupuncture in the treatment of psoriasis. The researcher used acupuncture at Backshu points combined with surrounded needling at local skin lesions to treat psoriasis vulgaris in resting stage, and it produced superior overall curative effect compared to that of the control group of qingdai compound capsule combined with external caspotriol after 3 months of treatment (19). Acupuncture combined with moxibustion was used to treat psoriasis, and the control group took acitretin capsule orally (20). After 12 weeks, it was found that the overall effective rate was 95% in the acupuncture and moxibustion group but 80% in the control group. There were no adverse reactions in the group of acupuncture combined with moxibustion, and 31 of the 40 patients in the control group had tolerable adverse reactions. Psoriasis with blood heat syndrome was treated with Tripterygium Glycosides Tablets combined with blood-letting therapy, and the control group was given Tripterygium Glycosides Tablets (21). The results showed that the total effective rate in the treatment group was 66.67%, on the other hand, that of the control group was only 50.00% (P<0.05). The clinical observation of fire acupuncture combined with cotton moxibustion was carried out on patients with plaque psoriasis (22). After eight weeks of clinical treatment, the PASI score and DLQI score of patients were significantly lower than those before treatment. All in all, acupuncture therapy provides a promising choice for the clinical treatment of psoriasis.

Acupuncture belongs to a broad family of clinical techniques, producing therapeutic effects by stimulating acupoints (23). Acupuncture has been used in China for more than 2,000 years (24), and has been widely recognized in the USA and other parts of the Western world (25). At present, acupuncture therapy is mostly used as an

adjuvant therapy to treat psoriasis, especially in the adjuvant treatment of psoriasis with traditional Chinese medicine. The study found that acupuncture and moxibustion combined with Liangxue Xiaovin Decoction can significantly improve the T-lymphocyte subsets and Th1/ Th2 levels in peripheral blood of erythroderma psoriasis patients (26). A combination of Huoxue Jiedu decoction with fire acupuncture was utilized to treat patients with blood-stasis psoriasis for 8 weeks, and the control group was only treated with Huoxue Jiedu Decoction for 8 weeks (27). The total effective rate in the study group was 88.68%, which was notably higher than 71.7% in the control group. Another study used Liangxue Xiaofeng Decoction combined with fire acupuncture to treat psoriasis vulgaris, while the control group used Liangxue Xiaofeng Decoction to treat psoriasis vulgaris (28). The results showed that both groups could reduce PASI score, and the experimental group was lower than the control group. At present, there are still some problems in acupuncture therapy. For example, there is no unified standard for the operation of fire acupuncture and the selection of needle tools. Therefore, acupuncture-assisted traditional Chinese medicine is better than acupuncture alone in the treatment of psoriasis.

Most noteworthy, the research on the mechanism of acupuncture and moxibustion in psoriasis treatment is constantly expanding. T cell-mediated immune response is the main factor promoting and leading to psoriasis (29). The study found that the proportion of CD4/CD8 in psoriatic lesions was higher than that in blood, suggesting that CD4 T cells were relatively increased, and the natural regression of psoriatic drip lesions was significantly related to the decrease of CD4 T cells and the intervention of CD8 T cells (30). Acupuncture therapy can significantly adjust the ratio of CD4/CD8, promote the transformation of CD4 to CD8, and reduce the release of CD4 T cell related cytokines (31). Neuropeptides and sensory nerve have crucial roles in the pathogenesis of psoriasis, and acupuncture therapy can regulate nerve excitability and neuropeptide level by regulating the release of a variety of neurotransmitters (acetylcholine, etc.) (32). In addition, acupuncture therapy can directly affect the local vascular system, inhibit the increase of vascular permeability in the process of inflammation, and reduce the local infiltration of inflammatory substances, so as to achieve the purpose of treating psoriasis (33). HSP has the effect of stress protection, and the expression of HSP27 and HSP70 disappears in the psoriatic epidermis (34,35). An experiment

also found that acupuncture and moxibustion can increase the expression of HSP70 mRNA and the content of HSP70 in local tissues (33).

All in all, acupuncture is an effective, safe, simple, economical, and easy to use for treating psoriasis, with a long-term action on the control of psoriasis symptoms, and has few side effects or toxicities (36). Therefore, acupuncture paratherapy has been widely accept for psoriasis treatment by physicians who wish to minimize the side effects brought by medication while maximizing its therapeutic effect. In recent years, an increasing number of systematic reviews (SRs) have been carried out to evaluate the potential therapeutic benefits of acupuncture for psoriasis; however, their conclusions are questionable due to the quality of primary studies or methodological flaws. A systematic overview of SRs/meta-analyses (MAs) is a rather novel research method for combining the outcomes from multiple SRs/MAs, assessing their quality and aiming to resolve inconsistencies. Thus, the present overview is aimed at investigating the scientific quality of relevant SRs/MAs with regard to the clinical application of acupuncture in psoriasis treatment from a critical perspective.

# Methods

# Studies searches

We performed an electronic literature search in eight databases, including China National Knowledge Infrastructure (CNKI), Chinese Biomedical Databases (CBM), Wanfang Databases, VIP Journals Database, PubMed, Cochrane Library, Embase, and the Web of Science from the dates of their inceptions to July 2021. The following search terms were used: "psoriasis", "acupuncture", "acupuncture therapy", "needle", "needling", "medicine, East Asian Traditional", "acupressure", "acupoint\*", "electro-acupuncture", "electroacupuncture", "traditional Chinese medicine", "SR", "systematic review", "systematic assessment", "systematic evaluation", "meta-analysis\*", and "Cochrane review".

# Inclusion criteria

#### Types of reviews

SRs with or without MA of randomized controlled trials (RCTs) in which acupuncture therapy was adopted to treat psoriasis were included. Repetitive papers, graduation

dissertations, and SRs/MAs that lacked rigorousness were not included.

# Types of participants

Participants must have been diagnosed with psoriasis according to any international or national diagnostic guidelines. Patients' age, gender, ethnicity, the length and stage of the disease were not restricted.

# Types of interventions

The intervention group included acupuncture therapy alone, as well as of a combination of fire needle therapy and other medications. For example, acupuncture therapy and acupuncture therapy plus oral/external Chinese medicine or plus oral/external Western medicine.

# Types of comparators

The control groups received oral/external Chinese medicine or oral/external Western medicine, and sham-acupuncture.

#### Types of outcomes

The severity and area of lesions in psoriasis patients are commonly evaluated by Psoriasis Area and Severity Index (PASI). Evaluation of the therapeutic results of acupuncture therapy in psoriasis treatment was mainly based on the curative rate, markedly effective rate, and improved rate of PASI. The secondary outcome indicators of the research included Traditional Chinese Medicine (TCM) syndrome score, QOL score, Hamilton Anxiety Scale (HAM-A) score, the incidence of adverse events, and the relapse rate. Moreover, we also summarized and analyzed the changes of inflammatory cells and cytokines to provide evidence for the study of its mechanism.

# Exclusion criteria

Literatures were excluded according to the following criteria: (I) the diagnostic criteria for psoriasis mentioned above were not used; (II) non-SR/MA; (III) duplicated publication or review comments; (IV) non-Chinese or English literatures; and (V) studies that did not include the full text.

#### Data extraction

All studies were read by two independent authors. According to the predefined criteria, the two authors also validated and extracted data from the studies. During the data extraction process, disagreements were settled by discussions with a third investigator.

#### Quality assessment

Methodological, reporting, and evidence quality, along with risks of bias were assessed by two independent authors using the Assessing the Methodological Quality of Systematic Reviews 2 (AMSTAR-2) tool (37), the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-A statements (38), the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system (39), and the Risk of Bias in Systematic Reviews (ROBIS) tool (40), respectively. Conflicting opinions were resolved through consulting a third investigator.

- (I) The AMSTAR-2 tool (37) was applied to evaluate the methodological quality of the included SRs. There were 16 items on the checklist, including 7 critical items (items 2, 4, 7, 9, 11, 13, and 15) used to evaluate the validity of SRs included. Each item within the AMSTAR-2 tool was answered with a "yes" (a positive result), a "partial yes" (partial adherence to the standard), or a "no" (absence of information for assessing an item), based on the level of adherence to the standard. After evaluating the defects found in all items, the general quality of work was divided into "high", "moderate", "low", or "critically low".
- (II) The PRISMA-A statements (38) published in 2019 is an extension of PRISMA and specifically used for acupuncture that contains a checklist of 27-item and a four-phase flow diagram, which aims to guide authors on improving the reporting quality of SRs regarding acupuncture intervention. It covers a total of seven aspects of SRs, including titles, abstracts, introductions, methodology, results, discussions, and funding. Each item was answered with "yes", "no", and "not applicable", and the completion of each item was expressed as a ratio.
- (III) The ROBIS tool (39) is commonly used by researchers to scrutinize the level of bias in an SR across four domains of two phases ("study eligibility criteria", "identification and selection of studies", "data collection and study appraisal", and "synthesis and findings"). Finally, the results were classed as




Figure 1 PRISMA flow chart of the study selection process.

having low, high, or unclear risk.

(IV) The GRADE system (41,42) uses four grading levels: very low, low, moderate, and high. The initial grading was based on five aspects: study limitations, indirectness of evidence, inconsistent results, lack of precision, and reporting bias.

#### Statistical analysis

This paper summarizes the data of the included systematic review (SRs)/meta-analysis (MAs), so a descriptive analysis is carried out.

# **Results**

#### Description of the screening process

According to the search strategy, we searched eight databases, and a total of 98 studies were selected. Thirtyseven duplicates were removed by EndNote (version X9, Clarivate Analytics) reference management software. Fortyfive studies were excluded after title/abstract screening. Eventually, seven SR/MAs were included in the present overview after full-texts inspection (43-49). The entire screening and process of selection is depicted in *Figure 1*.

#### Characteristics of SRs

A total of 79 RCTs and 6,773 patients were included among the seven SR/MAs, and the data extracted are shown in Table 1. All of these SRs were published between 2015 and 2020, including two English articles and five Chinese literatures. All included literatures assessed the clinical efficacy of acupuncture therapy in psoriasis vulgaris treatment. Acupuncture therapy was prescribed in the treatment group, while the control group received oral/ external Chinese medicine or oral/external Western medicine and sham-acupuncture group. The number of RCTs in the included literatures ranged between 6 and 17. For the evaluation of literature quality, the Jadad score was used in one SR (47), and the rest were evaluated in accordance with Cochrane Collaboration Risk of Bias Tool (43-46,48,49). Sensitivity analysis was used in three studies (44,47,48) and subgroup analysis was used in five studies (43-45,47,48). All SRs/MAs showed the efficiency of acupuncture therapy in treating psoriasis.

#### Methodological quality of included SRs

*Table 2* present an overview of methodological quality of the SRs included. The AMSTAR-2 instrument was used for the

| The presenting Research No. of study  | Research                    | No. of study                      |  |  |   | Assessing the                  | Was a meta               | Sensitivity/         |            |
|---|-----------------------------|-----------------------------------|--|--|---|--------------------------------|--------------------------|----------------------|------------|
| author and<br>publication year  | design                      |                                   | Interventional approach  | Control  | Outcomes  | methodological<br>quality      | analysis<br>carried out? | subgroup<br>analysis | Results    |
| Meaghan Coyle<br>[2015]   | RCT                         | 6 [522]                           | Acupuncture therapies<br>(either on its own or<br>combined with other TCM<br>approaches, including<br>point stimulation)   | No treatment, sham<br>acupuncture, or<br>Western medicines                             | PASI score, health-<br>related quality of life,<br>relapse rate, and<br>adverse events  | Cochrane risk<br>of bias tool  | Yes                      | No/yes               | Effective  |
| Liu Liu [2021]  | RCT                         | 16 [1,267]                        | Fire acupuncture, fire<br>needle therapy plus<br>oral/external Chinese<br>medicine or plus oral/<br>external Western<br>medicine   | TCM and oral/<br>external Chinese<br>medicine or oral/<br>external Western<br>medicine | PASI, TCM syndrome<br>scores, incidence of<br>adverse events, quality<br>of life score, HAM-A<br>score, recurrence<br>rate, changes of<br>inflammatory cells and<br>cytokines | Cochrane risk-<br>of-bias tool | Yes                      | Yes/yes              | Effective  |
| Yuhua Huang<br>[2019]   | RCT                         | 6 [527]                           | Bleeding combined with<br>electroacupuncture   | Conventional therapy   | PASI, effective rate  | Cochrane risk-<br>of-bias tool | Yes                      | No/yes               | Effective  |
| Meihong Li<br>[2020]  | RCT                         | 12 [1,088]                        | Fire acupuncture or<br>combined with other<br>conventional therapy   | TCM, Western<br>medicine, placebo<br>treatment   | PASI, TCM syndrome<br>scores  | Cochrane risk-<br>of-bias tool | Yes                      | No/no                | Effective  |
| Xingxing Wang<br>[2019]   | RCT                         | 17 [1,607]                        | Fire acupuncture<br>combined with TCM or<br>Western medicine   | Western medicine   | PASI, recurrence rates,<br>adverse reactions,<br>effective rate   | Jadad score                    | Yes                      | Yes/yes              | Effective  |
| Ran Sun [2015]  | RCT                         | 13 [1,293]                        | Acupuncture and<br>moxibustion therapy   | Western medicine or<br>placebo acupuncture   | PASI, DLQI score,<br>Npt score, adverse<br>reactions, effective<br>rate, TCM syndrome<br>scores   | Cochrane risk-<br>of-bias tool | Yes                      | Yes/yes              | Effective  |
| Jiahua Zou<br>[2020]  | RCT                         | 9 [469]                           | Acupuncture and<br>moxibustion therapy   | Conventional therapy   | PASI, adverse<br>reactions (itchy/<br>cutaneous<br>desquamation,<br>dry mouth), effective<br>rate, treatment cure<br>rate   | Cochrane risk-<br>of-bias tool | Yes                      | on/oN                | Effective  |
| RCT, randomized controlled trial; PASI, Psoria<br>Chinese medicine; HAM-A, Hamilton Anxiety Ratir | ed controlle<br>9; HAM-A, F | ed trial; PASI,<br>Hamilton Anxie | RCT, randomized controlled trial; PASI, Psoriasis Area Severity Index; DLQI, dermatological quality of life indicators; CM, Chinese medicine; TCM, traditional Chinese medicine; HAM-A, Hamilton Anxiety Rating Scale; Npt, Neopterin. | Index; DLQI, dermato<br>erin.  | logical quality of life in  | dicators; CM, C                | hinese medic             | ine; TCM, t          | raditional |

© Annals of Palliative Medicine. All rights reserved.

Table 1 Basic information of the included studies

#### Jing et al. Acupuncture for psoriasis: an overview of systematic reviews

 Table 2 Results of the AMSTAR-2 assessments (37)

| Item  | Meaghan<br>Coyle [2015] | Liu Liu<br>[2021] | Yuhua Huang<br>[2019] | Meihong Li<br>[2020] | Xingxing<br>Wang [2019] |    | Jiahua Zou<br>[2020] |
|---|-------------------------|-------------------|-----------------------|----------------------|-------------------------|----|----------------------|
| 1. Did the research questions and inclusion criteria for the review include the components of PICO?   | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
| 2. Did the report of the review contain an explicit<br>statement that the review methods were established<br>prior to the conduct of the review and did the report<br>justify any significant deviations from the protocol? | Ν                       | Ν                 | Ν                     | Ν                    | Ν                       | Ν  | Ν                    |
| 3. Did the review authors explain their selection of the study designs for inclusion in the review?   | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
| 4. Did the review authors use a comprehensive literature search strategy?   | PY                      | Y                 | PY                    | Y                    | PY                      | Y  | Y                    |
| 5. Did the review authors perform study selection in duplicate?   | Y                       | Y                 | Ν                     | PY                   | Y                       | Y  | Y                    |
| 6. Did the review authors perform data extraction in duplicate?   | Y                       | Y                 | PY                    | Y                    | Y                       | Y  | Y                    |
| 7. Did the review authors provide a list of excluded studies and justify the exclusions?  | Ν                       | Ν                 | Ν                     | Ν                    | Ν                       | Y  | Ν                    |
| 8. Did the review authors describe the included studies in adequate detail?   | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
| 9. Did the review authors use a satisfactory technique for assessing the RoB in individual studies that were included in the review?  | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
| 10. Did the review authors report on the sources of funding of studies included in the review?  | Y                       | Ν                 | Ν                     | Y                    | Y                       | Ν  | Y                    |
| 11. If meta-analysis was performed, did the review authors use appropriate methods for the statistical combination of results?  | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
| 12. If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis?  | Y                       | Y                 | PY                    | Y                    | Y                       | Y  | Ν                    |
| 13. Did the review authors account for RoB in<br>primary studies when interpreting/discussing the<br>results of the review?   | Y                       | Y                 | Ν                     | Ν                    | Y                       | Y  | Y                    |
| 14. Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review?  | Ν                       | Y                 | ΡY                    | PY                   | Y                       | Y  | Y                    |
| 15. If they performed quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review?                 | Y                       | Y                 | Ν                     | Ν                    | Y                       | Y  | Y                    |
| 16.Did the review authors report any potential<br>sources of conflict of interest, including any funding<br>they received for conducting the review?  | Y                       | Y                 | Ν                     | Y                    | Y                       | Ν  | Y                    |
| Quality   | CL                      | CL                | CL                    | CL                   | CL                      | CL | CL                   |

RoB, risk of bias; Y, yes; PY, partial yes; N, no; CL, critically low; L, low; H, high.

evaluation of methodological quality, which is developed from AMSTAR and contains 16 items. Items 2, 4, 7, 9, 11, 13, and 15 were used to critically evaluate the effectiveness of an SR. Considering that several critical items of the included SRs/MAs were not met, the final evaluation of methodological quality was critically low for seven SR/MAs.

#### Reporting quality of included SRs

The reporting quality of the included SRs using the PRISMA-A tool is summarized in *Table 3*. Generally, the reports were relatively comprehensive, but there were still some defects. In the "Methods" section, only one SRs/MAs (44) reported on the protocol and registration. Three SRs/MAs (44,47,48) presented detailed search, risk of bias across studies was presented in four SRs/MAs (44,47-49), and only two SRs/Mas (44,47) presented additional analyses. In the "Discussion" section, limitations were presented in four SRs/MAs (43,44,48,49). Funding information was presented in five SRs/MAs (43,44,46,47,49).

# Risk of bias of included SRs

With the ROBIS, all SRs/MAs were evaluated to bear low risk of bias in phase 1, which evaluated the relevance of the research topic. Phase 2 had four domains. Assessing the eligibility criteria of studies in Domain 1, the risk of bias of six SRs/MAs (43,44,46-49) was low. Domain 2 investigated study identification and inclusion, four SRs/MAs (44,47-49) were at a low bias risk. Domain 3 investigated the gathering and appraisal, in which six SRs/MAs (43,44,46-49) were classed as low risk of bias. For Domain 4, which evaluated the combination and results, five SRs/MAs (43,44,46,47,49) were at a high bias risk. In Phase 3, the risk of bias was considered overall, and two SRs/MAs (44,48) had a low risk. *Table 4* presents more detailed information.

#### Evidence quality of included SRs

This review contains seven SRs/MAs involving 27 outcomes. There was one high-quality evidence, seven moderate-quality evidences, and 19 outcomes in low-quality evidence. Due to the elevated risk of bias, lack of precision, inconsistent results, and indirectness, the evidence was downgraded. More details are provided in *Tables 5,6*. In addition, there were 25 outcome indicators of acupuncture therapy, including effective rate (n=7) and PASI score (n=15),

50% of lesion reduction (n=1), and relapse rate (n=2). Among these, there were eight moderate-quality evidences, 17 low-quality evidences, and no high-quality evidence.

# Efficacy of acupuncture for psoriasis

In the seven included SRs, the efficacy of acupuncture therapy in psoriasis treatment (acupuncture alone or acupuncture-based combination therapies) yielded superior results than the control treatments. The clinical efficacy of acupuncture therapy in psoriasis treatment was evaluated in five literatures, and it was considered to be effective: relative risk (RR) =1.20, 95% confidence interval (CI): 1.09-1.33, P=0.0002; RR =0.82, 95% CI: 0.71-0.95, P<0.006; odds ratio (OR) =2.42, 95% CI: 1.75-3.35, P<0.01; OR =3.06, 95% CI: 2.19-4.28, P<0.001; OR =2.63, 95% CI: 1.62-4.28, P<0.0001 (44-47,49). Four SRs/MAs (44,45,47,49) showed that acupuncture treatment of psoriasis could reduce the PASI score [mean difference (MD) =-1.32, 95% CI: -2.19 to -0.44, P=0.003; MD =0.97, 95% CI: 0.44-1.51, P<0.0004; weighted mean difference (WMD) =-2.65, 95% CI: -3.92 to -1.37, P<0.001; MD =-1.49, 95% CI: -2.16 to -0.83, P<0.0001]. One SRs/MAs (44) showed that fire needle did not significantly improve the QOL of patients (MD =-0.44, 95% CI: -1.11 to 0.24, P=0.21), but could significantly reduce the TCM syndrome score (MD = -0.72, 95% CI: -1.15 to -0.28, P=0.001), and did not reduce anxiety in patients with psoriasis by HAM-A score (MD =-0.16, 95% CI: -0.98 to 0.67, P=0.71). Two SRs/MAs (44,47) evaluated the relapse rate and found that it was low (RR =0.48, 95% CI: 0.29-0.80, P=0.005; OR =0.32, 95% CI: 0.17-0.60, P<0.05).

Simultaneously, in view of the numerous operation methods of acupuncture treatment, we also conducted a subgroup analysis. When the acupuncture group was compared with the oral Western medicine group, one SRs/ MAs (43) considered that there was a lack of statistical difference in improving Psoriasis Area and Severity Index assessment of 60% reductions (PASI 60), while another SRs/MAs (48) believed that there was a statistical difference in improving the PASI score, and thus, further investigation is needed in the future. When the electroacupuncture group was compared with control group that received shamacupuncture, one study (43) did not discover any significant difference in the PASI score between the two groups, and another study (48) reported that there was a lack of significant difference in the effective rate and PASI score between the two groups. When the electroacupuncture

#### Table 3 PRISMA-A results (38)

| Section/topic | Items                                  | Meaghan Coyle<br>[2015] | Liu Liu<br>[2021] | Yuhua Huang<br>[2019] | Meihong Li<br>[2020] | Xingxing<br>Wang [2019] |    | Jiahua Zou<br>[2020] |
|---------------|--|-------------------------|-------------------|-----------------------|----------------------|-------------------------|----|----------------------|
| Title         | 1. Title                               | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
| Abstract      | 2. Structured summary                  | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | Y                    |
| Introduction  | 3. Rationale                           | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | Y                    |
|               | 4. Objectives                          | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | Y                    |
| Methods       | 5. Protocol and registration           | Ν                       | Y                 | Ν                     | Ν                    | Ν                       | Ν  | Ν                    |
|               | 6. Eligibility criteria                | Y                       | Y                 | Υ                     | Y                    | Y                       | Υ  | Y                    |
|               | 7. Information sources                 | PY                      | Y                 | PY                    | Y                    | PY                      | Υ  | Y                    |
|               | 8. Search                              | Ν                       | Y                 | PY                    | PY                   | Y                       | Υ  | PY                   |
|               | 9. Study selection                     | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | Y                    |
|               | 10. Data collection process            | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | Y                    |
|               | 11. Data items                         | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
|               | 12. Risk of bias in individual studies | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
|               | 13. Summary measures                   | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | Y                    |
|               | 14. Synthesis of results               | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | Y                    |
|               | 15. Risk of bias across studies        | Ν                       | Y                 | Ν                     | Ν                    | Y                       | Υ  | PY                   |
|               | 16. Additional analyses                | PY                      | Y                 | PY                    | PY                   | Y                       | PY | Ν                    |
| Results       | 17. Study selection                    | Y                       | Y                 | Υ                     | Y                    | Y                       | Υ  | Y                    |
|               | 18. Study characteristics              | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | PY                   |
|               | 19. Risk of bias within studies        | Y                       | Y                 | Ν                     | Y                    | Y                       | Υ  | Y                    |
|               | 20. Results of individual studies      | s Y                     | Y                 | Ν                     | Ν                    | Y                       | Υ  | Y                    |
|               | 21. Synthesis of results               | Y                       | Y                 | Y                     | Y                    | Y                       | Υ  | Y                    |
|               | 22. Risk of bias across studies        | Y                       | Y                 | Ν                     | Y                    | PY                      | Υ  | Y                    |
|               | 23. Additional analysis                | Y                       | PY                | Ν                     | PY                   | Ν                       | Ν  | Ν                    |
| Discussion    | 24. Summary of evidence                | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
|               | 25. Limitations                        | Y                       | Y                 | PY                    | PY                   | Ν                       | Y  | Y                    |
|               | 26. Conclusions                        | Y                       | Y                 | Y                     | Y                    | Y                       | Y  | Y                    |
| Funding       | 27. Funding                            | Y                       | Y                 | Ν                     | Y                    | Y                       | Ν  | Y                    |

Y, yes; PY, partial yes; N, no.

|                      |   | Pha   | ase 2  |                                  | Phase 3                    |
|----------------------|---|---|--|----------------------------------|----------------------------|
| References           | Domain 1. study<br>eligibility criteria | Domain 2. identification and selection of studies | Domain 3. data collection<br>and study appraisal | Domain 4. synthesis and findings | Risk of bias in the review |
| Meaghan Coyle [2015] | ©                                       | 8   | ©  | ©                                | $\odot$                    |
| Liu Liu [2021]       | ©                                       | $\odot$   | ©  | ©                                | $\odot$                    |
| Yuhua Huang [2019]   | 8                                       | ?   | 8  | 8                                | 8                          |
| Meihong Li [2020]    | ©                                       | 8   | ©  | ©                                | $\otimes$                  |
| Xingxing Wang [2019] | ٢                                       | $\odot$   | $\odot$  | ©                                | $\otimes$                  |
| Ran Sun [2015]       | ٢                                       | $\odot$   | $\odot$  | 8                                | $\odot$                    |
| Jiahua Zou [2020]    | ©                                       | ©   | $\odot$  | ©                                | 8                          |

Table 4 Results of the ROBIS assessment (40)

⊙, low risk; ⊗, high risk; ?, unclear risk.

group was compared with oral Western medicine group, one SRs/MAs (48) implied that electroacupuncture produced more effective outcome than Western medicine in treating psoriasis (RR =1.13, 95% CI: 1.02-1.26, P=0.02) and improving the PASI score (standardised mean difference (SMD) =-0.35, 95% CI: -0.64 to -0.06, P=0.02). When bloodletting plus cupping was compared with tazarotene, one SRs/MAs (43) found that there were significant differences in the PASI score (MD =-0.54, 95% CI: -1.01 to -0.07) and relapse rate (RR =0.23, 95% CI: 0.05-0.99) between the two groups, and another SRs/MAs (49) had the same conclusion (effective rate, RR = 1.10, 95%CI: 1.01-1.21, P=0.03; PASI score, SMD =-0.21, 95% CI: -0.39 to -0.03, P=0.02). eOne SRs/MAs (44) confirmed that fire needle could improve the overall effect for psoriasis (RR =1.20, 95% CI: 1.09–1.33, P=0.0002), in which fire needle plus oral medications was more effective than oral medications without fire needle (RR =1.35, 95% CI: 1.16-1.57, P=0.0001). Furthermore, compared oral medications plus topical medications, the risk of PASI score increase is lower after fire needle combined with internal and external medications (MD =-0.53, 95% CI: -0.72 to -0.33, P=0.00001). Another SRs/MAs (47) analyzed fire needle combined therapy. When fire needle plus oral Western medicine was compared with oral Western medicine, there was a statistical difference in the PASI score (WMD = -1.05, 95% CI: -2.53 to -0.47, P<0.05); a statistical difference in PASI score (WMD =-2.17, 95% CI: -5.99 to 1.65, P=0.26) was discovered when the use of oral Chinese medicine alone was compared with its combined use with fire needle; when fire needle combined with oral Chinese medicine

was compared with oral Western medicine, there was a statistical difference in the PASI score (WMD =–1.12, 95% CI: –2.11 to –0.13, P=0.03); when fire needle incorporated with oral Chinese medicine plus oral Western medicine was compared with oral Western medicine, there was a statistical difference in the PASI score (WMD =–1.87, 95% CI: –2.59 to –1.15, P<0.0001). More details are provided in *Table 5*.

#### Safety of acupuncture for psoriasis

Among the seven included SRs/MAs, five evaluated the adverse events of acupuncture in psoriasis treatment (43,44,47-49). One SRs/MAs (43) found no adverse events in the acupuncture group, while dry skin, desquamation, pruritus, etc. all occurred in the control group. Another SRs/MAs (44) reported that adverse events of the fire needle group were comparable to that of the control (RR =0.67; 95% CI: 0.28–1.63, P=0.38), and the control group had a high incidence of anaphylaxis (RR =0.21; 95% CI: 0.05–0.95, P=0.04). The remaining three SRs/MAs (47-49) showed that the likelihood of adverse events was low in the acupuncture group, with statistical significance (OR =0.54, 95% CI: 0.32–0.93, P<0.05; OR =0.09, 95% CI: 0.04–0.20, P<0.00001; OR =0.06, 95% CI: 0.01–0.46, P=0.007).

#### Discussion

#### Summary of evidence

The present paper is the first overview of SRs that investigated the efficacy and safety of acupuncture

|                       |                                 |                 |                 | Certainty assessment | ment            |                         |                           |          |           |
|-----------------------|---------------------------------|-----------------|-----------------|----------------------|-----------------|-------------------------|---------------------------|----------|-----------|
| References            | Outcomes                        | Risk of<br>bias | Inconsistency   | Indirectness         | Imprecision     | Other<br>considerations | Relative effect (95% CI)  | P value  | Certainty |
| Liu Liu [2021]        | Overall<br>effect [13]          | Low risk        | Significant     | Significant          | Not significant | None                    | RR 1.20 (1.09 to 1.33)    | 0.0002   | Low:      |
|                       | PASI [10]                       | Low risk        | Not significant | Not significant      | Not significant | None                    | MD -1.32 (-2.19 to 0.44)  | 0.003    | High:     |
|                       | TCM syndrome<br>scores [6]      | At risk         | Not significant | Not significant      | Significant     | None                    | MD –0.72 (–1.15 to –0.28) | 0.001    | Low:      |
|                       | Adverse events Low risk<br>[10] | Low risk        | Significant     | Not significant      | Not significant | None                    | RR 0.67 (0.28 to 1.63)    | 0.38     | Moderate: |
|                       | Regarding<br>anaphylaxis [4]    | At risk         | Not significant | Significant          | Not significant | None                    | RR 0.21 (0.05 to 0.95)    | 0.04     | Low:      |
|                       | QoL [4]                         | At risk         | Not significant | Significant          | Not significant | None                    | MD -0.44 (-1.11 to 0.24)  | 0.21     | Low:      |
|                       | HARS [4]                        | At risk         | Not significant | Not significant      | Significant     | None                    | MD -0.16 (-0.98 to 0.67)  | 0.71     | Low:      |
|                       | Recurrence rate Low risk<br>[2] | Low risk        | Not significant | Significant          | Not significant | None                    | RR 0.48 (0.29 to 0.80)    | 0.005    | Moderate: |
|                       | Inflammatory<br>cells [4]       | At risk         | Not significant | Significant          | Not significant | None                    | MD 0.46 (-0.02 to 0.94)   | 0.06     | Low:      |
|                       | (CD)8+T<br>cells [4]            | At risk         | Not significant | Significant          | Not significant | None                    | MD -4.30 (-5.70 to -2.90  | <0.00001 | Low:      |
|                       | CD4+ T cells [4]                | At risk         | Not significant | Significant          | Not significant | None                    | MD 8.90 (6.41 to 11.39)   | <0.00001 | Low:      |
|                       | Ratio of CD4+/<br>CD8+ [4]      | At risk         | Not significant | Significant          | Not significant | None                    | MD 0.52 (0.43 to 0.61)    | <0.00001 | Low:      |
|                       | Inflammatory<br>cytokines       | At risk         | Not significant | Not significant      | Not significant | None                    | MD -7.86 (-18.02 to 2.29) | 0.13     | Moderate: |
| Yuhua Huang<br>[2019] | Effective<br>rate [6]           | At risk         | Not significant | Significant          | Significant     | None                    | RR 0.82 (0.71 to 0.95)    | <0.006   | Low:      |
|                       | PASI [3]                        | At risk         | Not significant | Not significant      | Significant     | None                    | MD 0.97 (0.44 to 1.51)    | <0.0004  | Low:      |
| Meihong Li<br>[2020]  | Effective<br>rate [12]          | At risk         | Significant     | Not significant      | Not significant | None                    | OR 2.42 (1.75 to 3.35)    | <0.01    | Low:      |
| Table 5 (continued)   | (pən.                           |                 |                 |                      |                 |                         |                           |          |           |

Table 5 Evidence quality results

| Table 5 (continued)     | tinued)  |                        |                          | Cortainty, accord    | +0000                  |                         |  |            |                 |
|-------------------------|--|------------------------|--------------------------|----------------------|------------------------|-------------------------|--|------------|-----------------|
|                         | I  |                        |                          | Certainty assessment | linent                 |                         |  |            |                 |
| References              | Outcomes   | Risk of<br>bias        | Inconsistency            | Indirectness         | Imprecision            | Other<br>considerations | Relative effect (95% CI)   | P value    | Certainty       |
| Xingxing<br>Wang [2019] | Effective<br>] rate [17]   | Low risk               | Not significant          | Significant          | Not significant        | None                    | OR 3.06 (2.19 to 4.28)   | <0.001     | Moderate:       |
|                         | PASI [17]  | Low risk               | Low risk Not significant | Significant          | Not significant        | None                    | WMD -2.65 (-3.92 to -1.37)   | <0.001     | Moderate:       |
|                         | Recurrence rate At risk<br>[3]   | At risk                | Significant              | Not significant      | Not significant        | None                    | OR 0.32 (0.17 to 0.60)   | <0.05      | Low:            |
|                         | Adverse<br>reactions [10]  | At risk                | Not significant          | Significant          | Not significant        | None                    | OR 0.54 (0.32 to 0.93)   | <0.05      | Low:            |
| Ran Sun<br>[2015]       | Adverse<br>reactions [5]   | At risk                | Not significant          | Not significant      | Significant            | None                    | OR 0.09 (0.04 to 0.20)   | <0.0001    | Low:            |
| Jiahua Zou<br>[2020]    | Effective rate [8] Low risk  | Low risk               | Significant              | Not significant      | Not significant        | None                    | OR 2.63 (1.62 to 4.28)   | <0.0001    | Moderate:       |
|                         | Cure rate [5]  | At risk                | Not significant          | Not significant      | Significant            | None                    | OR 2.96 (1.07 to 8.15)   | 0.04       | Low:            |
|                         | PASI [7]   | Low risk               | Significant              | Not significant      | Not significant        | None                    | MD -1.49 (-2.16 to -0.83)  | <0.001     | Moderate:       |
|                         | Skin Itch [5]  | At risk                | Significant              | Not significant      | Significant            | None                    | Not mentioned  | >0.05      | Low:            |
|                         | Erythema [2]   | At risk                | Not significant          | Significant          | Not significant        | None                    | OR 0.06 (0.01 to 0.46)   | 0.007      | Low:            |
|                         | Mouth<br>dryness [2]   | At risk                | Not significant          | Significant          | Not significant        | None                    | OR 0.03 (0.00 to 0.22)   | 0.0006     | Low:            |
| High,<br>difference: S  | High, ; moderate, ; low,<br>difference: SMD_standardized mean difference | ; low,<br>mean differe | /, ; very low,           |                      | bL, quality of life; C | )R, odds ratio; RF      | . QoL, quality of life; OR, odds ratio; RR, relative risk; MD, mean difference; WMD, weighted mean | rence; WMD | , weighted mean |
| מווומומוורמי י          | סועום, אומו ועמו עובדע   | ווובמוו חוווב          | lellce.                  |                      |                        |                         |  |            |                 |

|   |                             |                 | Cert  | Certainty assessment | lent                            |                         |                               |          |           |
|---|-----------------------------|-----------------|---|----------------------|---------------------------------|-------------------------|-------------------------------|----------|-----------|
| References  | Outcomes                    | Risk of bias    | Inconsistency                                   | Indirectness         | Imprecision                     | Other<br>considerations | - Relative effect<br>(95% CI) | P value  | Certainty |
| Acupuncture plus moxibustion vs. Western medicine | ustion vs. Western          | medicine        |   |                      |                                 |                         |                               |          |           |
| Meaghan Coyle [2015]                              | PASI60 [1]                  | Significant     | Not significant                                 | Significant          | Significant                     | None                    | RR 1.31 (0.87 to 1.97)        | **       | Low:      |
| Ran Sun [2015]                                    | Effective rate [12]         | Significant     | Significant                                     | Not significant      | Not significant Not significant | None                    | RR 1.14 (1.08 to 1.21)        | <0.00001 | Low:      |
|   | PASI [12]                   | Not significant | Not significant Not significant                 | Significant          | Not significant                 | None                    | SMD -0.29<br>(-0.41 to -0.18) | <0.00001 | Moderate: |
| Electroacupuncture vs. sham acupuncture           | ham acupuncture             |                 |   |                      |                                 |                         |                               |          |           |
| Meaghan Coyle [2015]                              | PASI [1]                    | Significant     | Not significant                                 | Significant          | Significant                     | None                    | MD 0.70 (-0.71 to 2.11)       | ** (     | Low:      |
| Ran Sun [2015]                                    | Effective rate [1]          | Significant     | Significant                                     | Not significant      | Not significant Not significant | None                    | RR 0.89 (0.60 to 1.32)        | 0.58     | Low:      |
|   | PASI [1]                    | Not significant | Not significant Not significant                 | Significant          | Not significant                 | None                    | SMD 0.47<br>(-0.06 to 1.01)   | 0.08     | Moderate: |
| Electroacupuncture vs. Western medicine           | Vestern medicine            |                 |   |                      |                                 |                         |                               |          |           |
| Ran Sun [2015]                                    | Effective rate [2]          | Significant     | Not significant Not significant Not significant | Not significant      | t Not significant               | None                    | RR 1.13 (1.02 to 1.26)        | 0.02     | Moderate: |
|   | PASI [2]                    | Not significant | Not significant Not significant                 | Significant          | Not significant                 | None                    | SMD -0.35<br>(-0.64 to -0.06) | 0.02     | Moderate: |
| Bloodletting plus cupping vs. tazarotene          | g vs. tazarotene            |                 |   |                      |                                 |                         |                               |          |           |
| Meaghan Coyle [2015]                              | PASI 50                     | Significant     | Not significant                                 | Significant          | Significant                     | None                    | RR1.47 (1.03 to 2.09)         | *        | Low:      |
|   | Relapse rate<br>(follow-up) | Significant     | Not significant                                 | Significant          | Significant                     | None                    | RR0.23 (0.05 to 0.99)         | *        | Low:      |
|   | PASI score                  | Significant     | Not significant                                 | Significant          | Significant                     | None                    | MD -0.54<br>(-1.01 to -0.07)  | *        | Low:      |
| Ran Sun [2015]                                    | Effective rate [5]          | Significant     | Significant                                     | Not significant      | Not significant Not significant | None                    | RR1.10 (1.01 to 1.21)         | 0.03     | Low:      |
|   | PASI [5]                    | Not significant | Not significant Not significant                 | Significant          | Not significant                 | None                    | SMD -0.21<br>(-0.39 to -0.03) | 0.02     | Moderate: |
| Point application therapy vs. halcinonide         | v vs. halcinonide           |                 |   |                      |                                 |                         |                               |          |           |
| Meaghan Coyle [2015]                              | Lesion<br>reduction (50%)   | Significant     | Significant                                     | Significant          | Not significant                 | None                    | RR 0.90 (0.79 to 1.02)        | * *      | Low:      |
|   | Relapse rate<br>(follow-up) | Significant     | Not significant                                 | Significant          | Not significant                 | None                    | RR 0.58 (0.33 to 1.00)        | * *      | Low:      |
| Table 6 (continued)                               |                             |                 |   |                      |                                 |                         |                               |          |           |

#### Jing et al. Acupuncture for psoriasis: an overview of systematic reviews

|   |   |                   | 00                              | Certainty assessment |                                 |                         | +                             |         |           |
|---|---|-------------------|---------------------------------|----------------------|---------------------------------|-------------------------|-------------------------------|---------|-----------|
| References  | Outcomes  | Risk of bias      | Inconsistency Indirectness      | Indirectness         | Imprecision                     | Other<br>considerations | - Relative effect<br>(95% CI) | P value | Certainty |
| Fire needle vs. topical medication  | nedication  |                   |                                 |                      |                                 |                         |                               |         |           |
| Liu Liu [2021]  | Overall effect [4]  | Significant       | Not significant                 |                      | Significant Not significant     | None                    | RR 1.15 (0.97 to 1.36)        | 0.11    | Low:      |
|   | PASI [2]  | Not significant   | Significant                     | Not significant      | Not significant Not significant | None                    | MD -0.48<br>(-1.14 to 0.19)   | 0.16    | Moderate: |
| Fire needle + oral medicine + topical medication vs. oral medicine + topical medication | cine + topical medic  | ation vs. oral m∈ | edicine + topical               | medication           |                                 |                         |                               |         |           |
| Liu Liu [2021]  | Overall effect [5]  | Significant       | Not significant                 | Significant          | Not significant                 | None                    | RR 1.14(0.82 to 1.59          | 0.44    | Low:      |
|   | PASI [5]  | Not significant   | Significant                     | Not significant      | Not significant Not significant | None                    | MD -0.53<br>(-0.72 to -0.33)  | <0.0001 | Moderate: |
| Fire needle + oral medicine vs. oral medicine   | cine vs. oral medicine  | (J)               |                                 |                      |                                 |                         |                               |         |           |
| Liu Liu [2021]  | Overall effect [4]  | Significant       | Not significant                 |                      | Significant Not significant     | None                    | RR 1.35 (1.16 to 1.57)        | 0.0001  | Low:      |
|   | PASI [2]  | Not significant   | Significant                     | Not significant      | Not significant Not significant | None                    | MD -4.30(-9.77 to 1.18)       | 0.12    | Moderate: |
| Xingxing Wang [2019]  | PASI [2] (Western<br>medicine)  | Significant       | Not significant                 |                      | Significant Not significant     | None                    | WMD -1.05<br>(-2.53 to -0.47) | <0.05   | Low:      |
|   | PASI [4] [Chinese<br>medicine]  | Significant       | Not significant                 | Significant          | Significant                     | None                    | WMD -2.17<br>(-5.99 to 1.65)  | 0.26    | Low:      |
|   | PASI [2] (Chinese<br>medicine vs.<br>Western medicine)                          | Significant       | Not significant Not significant | Not significant      | Significant                     | None                    | WMD -1.12<br>(-2.11 to -0.13) | 0.03    | Low:      |
|   | PASI [2] (Chinese<br>medicine +<br>Western medicine<br>vs. Western<br>medicine) | Significant       | Not significant                 | Significant          | Significant                     | None                    | WMD -1.87<br>(-2.59 to -1.15) | <0.0001 | Low:      |

© Annals of Palliative Medicine. All rights reserved.

therapy (acupuncture alone or acupuncturebased combination therapies) for psoriasis in recent years. Compared with previous similar articles, our study finally included more literatures, including the literatures on fire acupuncture. The design of the control group is richer in this paper. In addition to the western medicine group and sham/placebo acupuncture, there are also the combined treatment groups, such as oral medicine plus topical medication. Moreover, the databases searched in this article included Chinese and English databases, which has a wider retrieval range and the latest literatures. Our study suggested that compared to the control groups, acupuncture therapy of psoriasis, specifically in patients with psoriasis vulgaris, effectively improved skin lesions with few adverse events. Moreover, the acupuncture therapy group displayed a decent effect in improving the effective rate, as well as reducing the PASI score and relapse rate. All in all, the outcomes of this overview supported acupuncture paratherapy for psoriasis patients, but the result should still be interpreted cautiously due to the methodological flaws and low quality of the included SRs/MAs.

# Implications

This overview put forward certain challenges that authors of SRs should consider. We conducted a comprehensive analysis of the included literatures using AMSTAR-2, PRISMA, ROBIS, and other evaluation tools, and found that future research of this kind could be enhanced. Firstly, researchers should use AMSTAR-2, PRISMA, and ROBIS assessments to critically evaluate their work, so as to curtail the likelihood of subjective bias and enhance the quality of their research. Secondly, the quality of the included documents was generally low, and they must be registered in Prospero (http://www.crd.york.ac.uk/prospero) before publication of a meta-analysis, so as to reduce the risk of bias. Thirdly, it is necessary to provide a comprehensive research strategy for at least one database, as well as a list and explanation of those studies excluded. At the same time, in the data synthesis analysis, if the heterogeneity of the analysis results is significant, subgroup analysis or meta-regression analysis is needed to avoid publication bias. Finally, the source of funding should be stated, as the project sponsor may influence the results of the study.

Overall, compared with the treatments of the control groups, acupuncture therapy (acupuncture alone or acupuncture-based combination therapies) for psoriasis could improve the effective rate, and reduce the PASI score and relapse rate, despite some flaws in the seven included SR/MAs. Acupuncture therapy for psoriasis was generally effective and safe. In future, acupuncture therapy for psoriasis needs the support of more high-quality studies.

# Limitations

There are several limitations in this overview that should be noted. First of all, it is possible that certain information had been missed by us, therefore only SRs published in Chinese and English were included. Secondly, the sample size of our study was relatively small. Finally, this overview was also limited due to the subjective quality process. The personal beliefs of authors can also influence their judgment, so their direct results may be different.

# Conclusions

Our overview suggests that acupuncture could serve as a useful complementary therapy for psoriasis. Nevertheless, there is a lack of evidence of higher quality advocating these findings, studies with more rigorous design and larger population samples are necessary to provide stronger evidence for definitive conclusions.

# **Acknowledgments**

Funding: None.

# Footnote

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi. org/10.21037/apm-21-2523). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the

formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

# References

- Boehncke WH, Schön MP. Psoriasis. Lancet 2015;386:983-94.
- Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361:496-509.
- Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-20.
- 4. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133:377-85.
- 5. Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol 1996;35:633-9.
- Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014;70:512-6.
- Danielsen K, Olsen AO, Wilsgaard T, et al. Is the prevalence of psoriasis increasing? A 30-year followup of a population-based cohort. Br J Dermatol 2013;168:1303-10.
- 8. Kamiya K, Kishimoto M, Sugai J, et al. Risk Factors for the Development of Psoriasis. Int J Mol Sci 2019;20:4347.
- Svoboda SA, Ghamrawi RI, Owusu DA, et al. Treatment Goals in Psoriasis: Which Outcomes Matter Most? Am J Clin Dermatol 2020;21:505-11.
- Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011;303:1-10.
- Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-59.
- Canadian Psoriasis Guidelines Committee. Canadian guidelines for the management of plaque psoriasis. Ottawa, ON: Canadian Dermatology Association; 2009.
- Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009;(2):CD005028.
- Lebwohl M, Drake L, Menter A, et al. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol 2001;45:544-53.
- 15. Koo J. Systemic sequential therapy of psoriasis: a new paradigm for improved therapeutic results. J Am Acad

Dermatol 1999;41:S25-8.

- 16. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50.
- Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000;42:796-802.
- Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003;120:738-41.
- Jie S, Wu W, Du WL, et al. Clinical observation on 40 cases of psoriasis vulgaris treated by acupuncture at Backshu acupoint and local peripheral acupuncture. Chinese National and Folk Medicine 2015;24:61-2.
- Li LH, Li ZF. Clinical effect of acupuncture and moxibustion on 80 cases of psoriasis vulgaris. Imaging Research and Medical Application 2018;2:228-30.
- Cao XX, Zhang Y, Tan F. Efficacy of pricking collaterals and bloodletting combined with Tripterygium wilfordii polyglycoside tablets in the treatment of psoriasis with blood heat syndrome. Shanghai Medicine 2019;40:28-30.
- 22. Ji Y, Li WB, Lin YQ, et al. Discussion on the treatment of plaque psoriasis with fire needle combined with cotton moxibustion based on the "collateral disease theory". Journal of Liaoning University of Traditional Chinese Medicine 2021:1-12.
- 23. World Health Organization Regional Office for the Western Pacific: WHO International Standard Terminologies on Traditional Medicine in the Western Pacific Region. Manila, WPRO, 2007.
- 24. Wu JN. A short history of acupuncture. J Altern Complement Med 1996;2:19-21.
- Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008;12:1-23.
- 26. Li ZF, Li LH, Li XJ. Effects of acupuncture and medicine on T lymphocyte subsets and Th1/Th2 in peripheral blood of patients with erythroderma psoriasis and analysis of immunological mechanism. Sichuan Traditional Chinese Medicine 2018;36:173-5.
- Deng JL, Zhou LM, Zhou L. Therapeutic effect of Huoxue Jiedu decoction combined with fire acupuncture on psoriasis of blood stasis type and its effect on Th1/Th2 balance of peripheral blood. Shanxi Traditional Chinese Medicine 2019;40:103-5.
- 28. Dung G, Wang ZX. Effect of Liangxue Xiaofeng

#### Jing et al. Acupuncture for psoriasis: an overview of systematic reviews

decoction combined with fire acupuncture on the efficacy and T cell subsets of psoriasis vulgaris. Shanxi Traditional Chinese Medicine 2017;38:762-4.

- 29. Li CX, Liu YF. Pathogenesis of psoriasis: immunological evidence and prospect. Foreign medicine. Dermatology and Venereology 2000;3:175-7.
- Chen XS. Immunopathogenesis and immunotherapy of psoriasis. Foreign medicine. Dermatology and Venereology 1997;1:37-40.
- Li YL. 26 cases of erythroderma psoriasis treated by traditional Chinese medicine combined with acupoint injection. Journal of Liaoning University of Traditional Chinese Medicine 2009;11:101-2.
- Liang JT, Xia HM, Liao FZ. Systematic mechanism of acupuncture and moxibustion in the treatment of psoriasis. Sichuan Traditional Chinese Medicine 2007;4:97-9.
- Li ZR. Experimental acupuncture and moxibustion. Beijing: China Traditional Chinese Medicine Press 2003;212:182.
- Pang XW, Yang XQ. Study on clinical efficacy and mechanism of local electrostatic therapy in the treatment of psoriasis. Chinese Journal of Dermatology and Venereology 2002;16:224-6.
- Pang XW, Yang XQ, Meng RS, et al. Expression of heat shock protein in skin lesions and non-skin lesions of patients with psoriasis. Chinese Journal of Dermatology 1998;31:383-4.
- Xiang Y, Wu X, Lu C, et al. An overview of acupuncture for psoriasis vulgaris, 2009-2014. J Dermatolog Treat 2017;28:221-8.
- 37. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.
- Wang X, Chen Y, Liu Y, et al. Reporting items for systematic reviews and meta-analyses of acupuncture: the PRISMA for acupuncture checklist. BMC Complement Altern Med 2019;19:208.

**Cite this article as:** Jing M, Shi L, Zhang Y, Zhu M, Yuan F, Zhu B, Chen M, Ge X. Efficacy and safety of acupuncture therapy for psoriasis: an overview of systematic reviews. Ann Palliat Med 2021;10(10):10804-10820. doi: 10.21037/apm-21-2523

- Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
- Whiting P, Savović J, Higgins JP, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol 2016;69:225-34.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395-400.
- Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
- 43. Coyle M, Deng J, Zhang AL, et al. Acupuncture therapies for psoriasis vulgaris: a systematic review of randomized controlled trials. Forsch Komplementmed 2015;22:102-9.
- Liu L, Sun XY, Lu Y, et al. Fire Needle Therapy for the Treatment of Psoriasis: A Quantitative Evidence Synthesis. J Altern Complement Med 2021;27:24-37.
- 45. Huang Y. Meta analysis of bloodletting combined with electroacupuncture in the treatment of psoriasis vulgaris. World Latest Medical Information Abstracts 2019,19:153-5.
- 46. Li M, Zhao Y, Sun D, et al. Meta analysis on the efficacy of fire acupuncture in the treatment of psoriasis vulgaris. Shaanxi Traditional Chinese Medicine 2020;41:686-9.
- Wang XX, Wu Q, Ma XH, et al. Meta analysis on efficacy and safety of fire acupuncture in the treatment of psoriasis vulgaris. Journal of Acupuncture and Moxibustion 2019,35:53-60.
- Sun R. Systematic review and meta-analysis of acupuncture treatment for psoriasis vulgaris. Chengdu University of Traditional Chinese Medicine, 2015.
- Zou J, Gong L, Huang G, et al. Meta analysis of acupuncture treatment for psoriasis vulgaris. Hunan Journal of Traditional Chinese Medicine 2020;36:127-30.

(English Language Editor: A. Kassem)

#### 10820